Estrella Immunopharma (ESLA) Projected to Announce Earnings on Wednesday

Estrella Immunopharma (NASDAQ:ESLA) is expected to post its results before the market opens on Wednesday, September 2nd. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Estrella Immunopharma (NASDAQ:ESLA) last posted its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. On average, analysts expect Estrella Immunopharma to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Estrella Immunopharma Stock Performance

ESLA opened at $0.71 on Monday. The stock’s fifty day simple moving average is $0.82 and its 200 day simple moving average is $1.10. Estrella Immunopharma has a 1-year low of $0.63 and a 1-year high of $3.15. The stock has a market cap of $30.67 million, a PE ratio of -2.94 and a beta of 0.88.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.00.

Hedge Funds Weigh In On Estrella Immunopharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its stake in shares of Estrella Immunopharma by 1,045.7% during the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after purchasing an additional 111,779 shares during the period. Marshall Wace LLP bought a new stake in Estrella Immunopharma in the 4th quarter valued at $88,000. XTX Topco Ltd grew its holdings in Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after buying an additional 39,099 shares in the last quarter. Quadrature Capital Ltd acquired a new position in Estrella Immunopharma in the 4th quarter valued at $43,000. Finally, State Street Corp grew its holdings in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after buying an additional 20,900 shares in the last quarter. Institutional investors and hedge funds own 0.35% of the company’s stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.